UK Markets open in 3 hrs

Celyad SA (CYAD.BR)

Brussels - Brussels Delayed price. Currency in EUR
Add to watchlist
4.2000+0.0200 (+0.48%)
At close: 5:29PM CEST
Full screen
Previous close4.1800
Open4.2000
Bid0.0000 x 0
Ask0.0000 x 0
Day's range4.0850 - 4.2200
52-week range3.4350 - 8.2900
Volume14,587
Avg. volume28,150
Market cap63.022M
Beta (5Y monthly)1.48
PE ratio (TTM)N/A
EPS (TTM)-1.2560
Earnings date04 Aug 2021 - 09 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Celyad Oncology to Present New Data on Allogeneic CAR T Therapy Program at the Society for Immunotherapy of Cancer Annual Meeting

    Conference to take place both in-person in Washington D.C. and virtually November 10-14, 2021MONT-SAINT-GUIBERT, Belgium, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that three abstracts about the Company’s allogeneic CAR T therapy programs will be presented at the Society for Immunotherapy of Cancer

  • Globe Newswire

    Celyad Oncology Announces September 2021 Conferences Schedule

    MONT-SAINT-GUIBERT, Belgium, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate at the following conferences in September 2021: 2021 Wells Fargo Virtual Healthcare ConferenceDates: Thursday, September 9 – Friday, September 10, 2021Presentation date: Thursday, September

  • Globe Newswire

    Celyad Oncology Reports First Half 2021 Financial Results and Recent Business Highlights

    •Enrollment continues at dose level three in Phase 1 IMMUNICY-1 trial evaluating CYAD-211 in relapsed/refractory multiple myeloma (r/r MM); next clinical update expected by year-end 2021 •Phase 1b KEYNOTE-B79 trial set to evaluate CYAD-101 with KEYTRUDA® in metastatic colorectal cancer (mCRC) patients with microsatellite stable disease on-track to begin in the fourth quarter of 2021 •IND-enabling studies in progress for first-in-class shRNA-based allogeneic, IL-18-armored CAR T candidate CYAD-20